Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) disclosed an insider transaction involving its Chief Commercial Officer, Lauren Merendino. On February 17, 2026, Merendino sold 5,814 shares of the company’s common stock for an aggregate amount of approximately $67,447. The disposal was executed at a weighted average price of $11.6009 per share, with the individual sale prices spanning from $11.195 to $11.8508.
The filing indicates that Merendino had previously exercised equity awards on February 15, 2026. She converted a total of 15,162 restricted stock units (RSUs) into an equivalent number of shares of Day One Biopharmaceuticals’ common stock. According to the filing, these RSUs represent contingent rights to receive one share per settled unit and the reported exercises did not require an out-of-pocket payment by Merendino.
Company performance and guidance
In a separate update, Day One Biopharmaceuticals reported preliminary net product revenue for 2025 of $155.4 million for its OJEMDA product, which the company said represents a 172% year-over-year increase. For 2026, management provided U.S. net product revenue guidance for OJEMDA in a range between $225 million and $250 million. At the midpoint, that guidance equates to projected year-over-year growth of 53% compared with 2025 preliminary results.
Corporate and strategic moves
Day One also announced completion of its acquisition of Mersana Therapeutics. The transaction was completed at a cash price of $25 per share plus a contingent value right that can be worth as much as $30.25 per share. Following the close, Mersana became a wholly owned subsidiary of Day One and its shares ceased trading on the Nasdaq exchange.
Analyst coverage
Market research firms have updated their views on Day One following recent developments. TD Cowen initiated coverage with a Buy rating and set a price target of $34.00. H.C. Wainwright reiterated its Buy rating and maintained a $25.00 price target after positive results from the FIREFLY-1 trial, which the firm summarized as showing that 77% of patients remained treatment-free for at least 12 months and that the median time to next treatment was 42.6 months.
The filings and corporate disclosures present a snapshot of insider activity coupled with operational updates - from strong reported OJEMDA sales growth and forward guidance to a completed acquisition and fresh analyst interest. The company’s regulatory filings document the precise terms of the insider sale and the RSU exercises, while separate corporate announcements provide the revenue, guidance, acquisition terms and clinical trial outcomes cited by analysts.